Race against time: drug trial aims to slow devastating ALS progression
NCT ID NCT01492686
Summary
This study tested whether a drug called MCI-186 (now known as edaravone) could slow the worsening of ALS symptoms. It involved 137 people with early-stage ALS who could still manage daily activities independently. For 24 weeks, participants received either the drug or a placebo through an IV drip to see if it helped maintain their physical abilities and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Study site
Osaka, Japan
Conditions
Explore the condition pages connected to this study.